Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294776 | 0.84 | PLK1 (0.61) | HDAC6HDAC8HDAC2CA1CA2 | |
| SCHEMBL958453 | 0.84 | MPO (0.55) | HDAC1HDAC3CA1CA2 | |
| SCHEMBL10261106 | 0.84 | CA12 (0.49) | HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL14880165 | 0.82 | SCN5A (0.56) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL51622 | 0.81 | ALDH1A1 (0.52) | — | |
| SCHEMBL10294732 | 0.79 | MLYCD (0.53) | — | |
| SCHEMBL13492270 | 0.79 | LMNA (0.53) | — | |
| SCHEMBL10294734 | 0.79 | KDM4E (0.57) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL4579781 | 0.79 | MAPT (0.51) | — | |
| SCHEMBL455156 | 0.79 | HCAR3 (0.55) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2011106632-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | HDAC1 3/4885HDAC6 1/4885HDAC8 15/4885 |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | HDAC1 3/4885HDAC6 1/4885HDAC8 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.